CDKN2A and female reproductive system neoplasm: In the present article, after a state of the art regarding p16 diagnostic applications in gynecological pathology, we have reported our experience with a novel antibody: p16ink4a (BC42) [Biocare Medical group-Paceco USA; Bioptica Milan], and its expression was tested across all different gynecologic neoplasms and compared to the traditional E6H4 clone (Ventana Medical Systems-Arizona USA; Roche).